Clebudin to show excellent clinical results against B hepatitis.

Published: 2001-11-19 06:56:00

Updated: 2001-11-19 06:56:00

Clebudin, a new therapeutic agent against B type hepatitis developed by Bukwang, has shown far outstanding clinical profiles compared to drugs already on markets. Its clinical study was reported by Prof. Lee Hyo-suk, Seoul National Univ. Medical School, and Prof. Jaque Maslini of France in the 52...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK